Novel Anti-Mitotic Peptides for the treatment of Cancer

Feb. 22, 2008

Novel Anti-Mitotic Peptides for the treatment of Cancer

Technology description

Description

Using peptide-array technology Researcher from the Universite d'Angers, INSERM and McGill University have identified peptides with sequence homology to multiple types of intermediate filaments that bind tubulin. Intermediate filaments are highly cell type specific. It has been demonstrated biochemically that the peptides prevent the polymerization of tubulin but do not affect existing microtubules. Both biochemical and in-vitro experiments show that this activity is sequence specific. Furthermore, human glioma cells naturally take up the peptides causing tubulin to agregate and cell division to arrest. Peptide administration is effective in delaying or, in some cases, completely preventing progression of transplanted glioblastoma cells in vivo. This makes these peptides prime candidates for the control of pathologies caused by cell proliferation such as cancer and infectious diseases

Application area

Because cancer is characterized by abnormal cell proliferation and migration, agents that affect mitosis and cell migration have great therapeutic potential. However, existing agents with these properties such as Taxol and Colchicine act on all cell types and cause significant side effects. Thus there is a need for anti-mitotic agents with greater cell specificity and reduced toxicity.

由于技术保密工作限制，技术信息无法完全展现，请通过邮箱或短信联系我们，获取更多技术资料。

More information

Institution

McGill University

Keywords:

peptide-array technology researcher

affect existing microtubules

in-vitro experiments show

completely preventing progression

transplanted glioblastoma cells

下载 PDF 文档

Technologies